Paradigm Biocapital Advisors LP Makes New Investment in Insmed, Inc. $INSM

Key Points

• Paradigm Biocapital Advisors LP has acquired 451,359 shares of Insmed, valued at approximately $34.43 million, making it 1.6% of the firm's total holdings.
• Major hedge funds, including Vanguard Group and Price T Rowe Associates, have boosted their positions in Insmed during the first quarter, indicating increased institutional interest in the stock.
• Insmed recently reported a loss of ($1.70) EPS for the quarter, missing estimates, despite an 18.9% increase in revenue year-over-year.

Paradigm Biocapital Advisors LP acquired a new position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 451,359 shares of the biopharmaceutical company's stock, valued at approximately $34,434,000. Insmed makes up about 1.6% of Paradigm Biocapital Advisors LP's investment portfolio, making the stock its 17th biggest position. Paradigm Biocapital Advisors LP owned about 0.25% of Insmed at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Insmed by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company's stock worth $1,393,675,000 after purchasing an additional 49,149 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Insmed by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company's stock worth $985,938,000 after purchasing an additional 219,131 shares in the last quarter. Northern Trust Corp grew its position in Insmed by 19.9% in the 4th quarter. Northern Trust Corp now owns 1,750,642 shares of the biopharmaceutical company's stock worth $120,864,000 after purchasing an additional 290,678 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Insmed by 3.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,602,655 shares of the biopharmaceutical company's stock worth $122,267,000 after purchasing an additional 56,048 shares in the last quarter. Finally, Westfield Capital Management Co. LP grew its position in Insmed by 49.9% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,406,609 shares of the biopharmaceutical company's stock worth $107,310,000 after purchasing an additional 468,058 shares in the last quarter.

Insmed Trading Down 0.7%

Shares of Insmed stock traded down $1.05 on Thursday, hitting $142.45. The stock had a trading volume of 1,179,587 shares, compared to its average volume of 2,799,221. The company has a quick ratio of 6.33, a current ratio of 6.68 and a debt-to-equity ratio of 0.45. Insmed, Inc. has a one year low of $60.40 and a one year high of $146.84. The stock has a market cap of $30.11 billion, a price-to-earnings ratio of -24.95 and a beta of 0.97. The stock's 50-day simple moving average is $112.91 and its two-hundred day simple moving average is $88.79.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. During the same period in the previous year, the business earned ($1.94) EPS. The business's revenue was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Insmed, Inc. will post -4.56 EPS for the current year.

Wall Street Analysts Forecast Growth

INSM has been the subject of several recent analyst reports. Truist Financial boosted their price objective on shares of Insmed from $126.00 to $139.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. The Goldman Sachs Group lifted their target price on shares of Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. HC Wainwright lifted their price target on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Wednesday, June 11th. William Blair began coverage on shares of Insmed in a research note on Wednesday, August 20th. They set an "outperform" rating on the stock. Finally, Leerink Partners lifted their price target on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, June 10th. Sixteen investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Insmed presently has an average rating of "Moderate Buy" and a consensus target price of $134.79.

Insider Buying and Selling

In related news, CEO William Lewis sold 6,865 shares of the firm's stock in a transaction on Monday, August 18th. The stock was sold at an average price of $128.40, for a total value of $881,466.00. Following the completion of the sale, the chief executive officer owned 233,924 shares of the company's stock, valued at $30,035,841.60. This trade represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Michael Alexander Smith sold 933 shares of the firm's stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $102.51, for a total value of $95,641.83. Following the completion of the sale, the insider directly owned 66,394 shares of the company's stock, valued at $6,806,048.94. The trade was a 1.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 511,048 shares of company stock valued at $51,089,294 over the last three months. Insiders own 3.00% of the company's stock.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.